If CMS cannot persuade GRAIL of the importance of randomization and using cancer death as the outcome, then it should cancel the study. The magnitude of the problem was evident in a major National ...
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma One hundred eighty-six patients were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results